Viking Therapeutics Completes Enrollment for Phase 3 VANQUISH-2 Study of VK2735 for Obesity Treatment Viking Therapeutics has completed patient enrollment in the Phase 3 VANQUISH-2 trial, aimed at evaluating VK2735 for obesity and type 2 diabetes. The study includes approximately 1,000 participants and will assess the drug's efficacy over 78 weeks.

Viking Therapeutics Completes Enrollment for Phase 3 VANQUISH-2 Study of VK2735 for Obesity Treatment #United_States #San_Diego #Clinical_Trial #Viking_Therapeutics #VK2735

Viking Therapeutics Unveils Promising Results in Obesity Treatments with VK2735 Pipeline Viking Therapeutics shared significant advancements in their VK2735 drug pipeline aimed at obesity treatment. Key developments include Phase 3 trials and promising financial updates.

Viking Therapeutics Unveils Promising Results in Obesity Treatments with VK2735 Pipeline #United_States #San_Diego #Viking_Therapeutics #VK2735 #Phase_3_Trials

Viking Therapeutics Releases Exciting Phase 2 Trial Results for VK2735 in Treating Obesity Viking Therapeutics presents promising results from the Phase 2 VENTURE trial of VK2735, showcasing significant weight loss and safety in patients.

Viking Therapeutics Releases Exciting Phase 2 Trial Results for VK2735 in Treating Obesity #None #San_Diego #Viking_Therapeutics #VK2735 #VENTURE_Trial

Viking Therapeutics Completes Enrollment for VK2735 Clinical Trial Focusing on Obesity Treatment Viking Therapeutics has successfully completed patient enrollment for its clinical trial on VK2735, exploring innovative obesity treatments in alignment with maintenance dosing regimens.

Viking Therapeutics Completes Enrollment for VK2735 Clinical Trial Focusing on Obesity Treatment #USA #San_Diego #Viking_Therapeutics #Obesity_Treatment #VK2735

Viking Therapeutics Welcomes Neil Aubuchon as New Chief Commercial Officer Viking Therapeutics has appointed Neil Aubuchon as Chief Commercial Officer, bringing over 20 years of experience to advance their metabolic therapies.

Viking Therapeutics Welcomes Neil Aubuchon as New Chief Commercial Officer #United_States #San_Diego #Viking_Therapeutics #VK2735 #Neil_Aubuchon

Viking Therapeutics Completes Enrollment in Phase 3 Trial for Obesity Treatment VK2735 Viking Therapeutics announces the successful completion of patient enrollment ahead of schedule in its Phase 3 VANQUISH-1 trial for obesity treatment VK2735.

Viking Therapeutics Completes Enrollment in Phase 3 Trial for Obesity Treatment VK2735 #United_States #San_Diego #Viking_Therapeutics #Obesity_Treatment #VK2735

Viking Therapeutics Unveils Promising Results from VK2735 Obesity Program at ObesityWeek 2025 Viking Therapeutics presented key clinical data from their VK2735 obesity program at ObesityWeek 2025, showcasing improvements in cardiometabolic health.

Viking Therapeutics Unveils Promising Results from VK2735 Obesity Program at ObesityWeek 2025 #USA #San_Diego #Viking_Therapeutics #VK2735 #ObesityWeek

Viking Therapeutics to Present VK2735 Clinical Data at ObesityWeek 2025 Viking Therapeutics plans to showcase clinical data from VK2735, aimed at treating obesity, with two key presentations at ObesityWeek 2025 in Atlanta.

Viking Therapeutics to Present VK2735 Clinical Data at ObesityWeek 2025 #United_States #Atlanta #Viking_Therapeutics #VK2735 #ObesityWeek

Viking Therapeutics Unveils Third Quarter 2025 Financial Results and Update on Clinical Advances Viking Therapeutics reports Q3 2025 financial results, highlighting positive developments in clinical programs for obesity treatment.

Viking Therapeutics Unveils Third Quarter 2025 Financial Results and Update on Clinical Advances #United_States #San_Diego #Viking_Therapeutics #VK2735 #VANQUISH_Trials

Viking Therapeutics Launches Clinical Trial for VK2735 Maintenance Dosing in Obesity Patients Viking Therapeutics has initiated a clinical trial to explore VK2735 maintenance dosing methods for obesity patients, aiming to support sustained weight loss.

Viking Therapeutics Launches Clinical Trial for VK2735 Maintenance Dosing in Obesity Patients #USA #San_Diego #Viking_Therapeutics #Obesity_Treatment #VK2735

Viking Therapeutics Achieves Significant Weight Loss with VK2735 in Phase 2 Trial for Obesity Treatment Viking Therapeutics reports promising results from its Phase 2 trial of VK2735, demonstrating significant weight loss in patients with obesity through daily dosing over 13 weeks.

Viking Therapeutics Achieves Significant Weight Loss with VK2735 in Phase 2 Trial for Obesity Treatment #United_States #San_Diego #Viking_Therapeutics #Obesity_Treatment #VK2735

Viking Therapeutics Reports Q2 2025 Financial Results and Future Plans Viking Therapeutics shared its financial results for Q2 2025, highlighting key clinical developments and ongoing trials for obesity therapies VK2735.

Viking Therapeutics Reports Q2 2025 Financial Results and Future Plans #USA #San_Diego #Viking_Therapeutics #Obesity_Treatment #VK2735

Viking Therapeutics Launches Phase 3 Clinical Trials for VK2735 in Obesity Treatment Viking Therapeutics has begun its Phase 3 clinical studies for VK2735, aimed at treating obesity and type 2 diabetes, marking a significant step in metabolic disorder therapies.

Viking Therapeutics Launches Phase 3 Clinical Trials for VK2735 in Obesity Treatment #USA #San_Diego #Viking_Therapeutics #VK2735 #GLP-1/GIP

Viking Therapeutics Reports Strong Financial Results for Q1 2025 Alongside Promising Clinical Updates Viking Therapeutics has released robust Q1 2025 financial results and key updates on its clinical pipeline. The company shows progress in obesity treatments, particularly VK2735.

Viking Therapeutics Reports Strong Financial Results for Q1 2025 Alongside Promising Clinical Updates #USA #San_Diego #Viking_Therapeutics #Obesity_Treatments #VK2735

Viking Therapeutics Completes Enrollment in Phase 2 Trial of VK2735 for Obesity Treatment Viking Therapeutics has announced the completion of enrollment for its Phase 2 VENTURE study of VK2735, a promising treatment for obesity. Data results are expected in late 2025.

Viking Therapeutics Completes Enrollment in Phase 2 Trial of VK2735 for Obesity Treatment #United_States #San_Diego #Viking_Therapeutics #obesity #VK2735

Viking Therapeutics Forms Strategic Alliance With CordenPharma for VK2735 Production Viking Therapeutics has secured a multi-year agreement with CordenPharma to support the manufacturing and commercialization of its VK2735 obesity treatment, ensuring a steady supply of API and final products for market demand.

Viking Therapeutics Forms Strategic Alliance With CordenPharma for VK2735 Production #United_States #San_Diego #Viking_Therapeutics #VK2735 #CordenPharma

Viking Therapeutics Unveils 2024 Fourth Quarter and Year-End Results with Promising Developments Viking Therapeutics announces its financial results for Q4 and full-year 2024, showcasing advances in clinical trials and a strong fiscal position.

Viking Therapeutics Unveils 2024 Fourth Quarter and Year-End Results with Promising Developments #United_States #San_Diego #Viking_Therapeutics #VK2735 #VK2809

Viking Therapeutics Kicks Off Phase 2 Trial for VK2735 as Obesity Treatment Viking Therapeutics has initiated a Phase 2 clinical trial for VK2735, a promising oral treatment aimed at combating obesity. This trial marks a significant step in development.

Viking Therapeutics Kicks Off Phase 2 Trial for VK2735 as Obesity Treatment #United_States #San_Diego #Viking_Therapeutics #Obesity_Treatment #VK2735

Investigation Launched by Pomerantz Law Firm for Viking Therapeutics Investors Amid Concerns Over Securities Fraud Pomerantz LLP is investigating potential securities fraud claims involving Viking Therapeutics, Inc. following fluctuating stock prices and trial data concerns.

Investigation Launched by Pomerantz Law Firm for Viking Therapeutics Investors Amid Concerns Over Securities Fraud #United_States #New_York #Pomerantz_LLP #Viking_Therapeutics #VK2735

Komkurrenz für Ozempic und Wegovy: Neue Abnehmspritze könnte noch viel schneller wirken Abnehmspritzen wie Wegovy und Ozempic sind sehr beliebt. Nun könnte ein neues Produkt dazukommen, das noch viel schneller wirken könnte.

Nach #Ozempic und #Wegovy
Neue #Abnehmspritze könnte noch viel schneller wirken - #VK2735

Abnehmspritzen wie Wegovy sind sehr beliebt. Nun könnte ein neuer Wirkstoff dazukommen. Einer ersten Studie zufolge ist er fünfmal wirksamer als die Konkurrenz.

www.watson.ch/internationa...

Neue Anti-Fettspritze wirkt fünf Mal schneller als Ozempic und Wegogy Abnehmspritzen wie Ozempic haben die Welt des Gewichtsverlusts revolutioniert. Nun drängt ein neues Produkt auf den Markt – das fünf Mal schneller wirkt.

#VK2735
Neue Anti-Fettspritze wirkt fünf Mal schneller als #Ozempic und #Wegovy

www.focus.de/finanzen/boe...